Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Stavudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.64 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.64 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | POLG | P54098 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 8/20 | 0.39 |
| ▸ | TK2 | O00142 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stavudine SCHEMBL28086387 | 1.00 | ALB (0.64) | ALBLMNACACNA1FMAPTCACNA1D | |
| Didanosine SCHEMBL23925471 | 0.86 | ALB (0.50) | ALBLMNACACNA1FMAPTCACNA1D | |
| Stavudine SCHEMBL4405002 | 0.86 | ALB (0.66) | ALBLMNACACNA1FMAPTCACNA1D | |
| Lamivudine SCHEMBL22364335 | 0.86 | ALB (0.65) | ALBLMNACACNA1FMAPTCACNA1D | |
| Stavudine SCHEMBL7053412 | 0.86 | LMNA (0.60) | ALBLMNACACNA1FMAPTCACNA1D | |
| Stavudine SCHEMBL8185422 | 0.86 | LMNA (0.60) | ALBLMNACACNA1FMAPTCACNA1D | |
| Nevirapine SCHEMBL1898785 | 0.83 | LMNA (0.46) | ALBLMNACACNA1FMAPTCACNA1D | |
| Nevirapine SCHEMBL29379693 | 0.83 | LMNA (0.46) | ALBLMNACACNA1FMAPTCACNA1D | |
| Lamivudine SCHEMBL465678 | 0.80 | ALB (1.00) | ALBLMNACACNA1FMAPTCACNA1D | |
| Lamivudine SCHEMBL2422788 | 0.80 | ALB (1.00) | ALBLMNACACNA1FMAPTCACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101768152-A | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORP | 2010-07-07 | — | — | CN | disclosed |
| CN-100591678-C | Piperidine derivatives as CCR5 antagonists | SCHERING CORP | 2010-02-24 | — | — | CN | disclosed |
| CN-100490811-C | Piperazine derivative used as CCRS antagonist | SCHLING (US) | 2009-05-27 | — | — | CN | disclosed |
| CN-101426781-A | CCR5 antagonists useful for treating HIV | SCHERING CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| EP-1933823-A1 | PHARMACEUTICAL COMPOSITION ON BASIS OF REVERSE TRANSCRIPTASE INHIBITOR AND MELDONIUM | "Grindeks" Public Joint Stock Company (LV) | 2008-06-25 | — | — | EP | disclosed |
| EP-1912671-A2 | BETA-GLUCURONIDE-LINKER DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| CN-101163695-A | Piperidinylpiperazine derivatives as chemokine receptor inhibitors | SCHERING CORP (US) | 2008-04-16 | — | — | CN | disclosed |
| CN-101133050-A | Piperidinyl piperidines as chemokine receptor inhibitors | SCHERING CORP (US) | 2008-02-27 | — | — | CN | disclosed |
| CN-1304389-C | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORP (US) | 2007-03-14 | — | — | CN | disclosed |
| WO-2007021164-A1 | PHARMACEUTICAL COMPOSITION ON BASIS OF REVERSE TRANSCRIPTASE INHIBITOR AND MELDONIUM | LATVIAN INSTITUE OF ORGANIC SYNTHESIS (LV) | 2007-02-22 | — | — | WO | disclosed |
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
| CN-1500078-A | Aryl oxime-piperazines useful as CCR5 antagonists | ���鹫˾ | 2004-05-26 | — | — | CN | disclosed |
| CN-1151131-C | Piperidine derivatives as CCR5 antagonists | ���鹫˾ | 2004-05-26 | — | — | CN | disclosed |
| CN-1481251-A | Combination methods for treating viral infections | ���鹫˾ | 2004-03-10 | — | — | CN | disclosed |
| CN-1450992-A | piperazine derivatives useful as CCR5 antagonists | SCHERING CORP (US) | 2003-10-22 | — | — | CN | disclosed |
| US-6528510-B1 | Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| CN-1349504-A | Piperidine derivatives as CCR5 antagonists | SCHERING CORP (US) | 2002-05-15 | — | — | CN | disclosed |
| CN-1349408-A | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy | SCHERING CORP (US) | 2002-05-15 | — | — | CN | disclosed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | ALB 4309/4885LMNA 3098/4885CACNA1F 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.